Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma by Weber, Thomas et al.
© 2014 Weber et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
OncoTargets and Therapy 2014:7 645–654
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
645
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S59983
stage-dependent prognostic impact of molecular 
signatures in clear cell renal cell carcinoma
Thomas Weber1,2
Matthias Meinhardt3
stefan Zastrow1
andreas Wienke4
Kati erdmann1
Jörg hofmann1
susanne Fuessel1
Manfred P Wirth1
1Department of Urology, Technische 
Universität Dresden, Dresden, 
germany; 2Department of Oncology 
and hematology, Martin-luther-
University halle-Wittenberg, halle 
(saale), germany; 3institute of 
Pathology, Technische Universität 
Dresden, Dresden, germany; 4institute 
of Medical epidemiology, Biostatistics, 
and informatics, Martin-luther-
University halle-Wittenberg, halle 
(saale), germany
correspondence: Thomas Weber 
Department of Oncology and  
hematology, Martin-luther-University 
halle-Wittenberg, ernst-grube-strasse 40, 
06120 halle (saale), germany 
Tel +49 345 557 7285 
Fax +49 345 557 7247 
email thomas.weber@medizin.uni-halle.
de 
 
susanne Fuessel 
Department of Urology, Technische 
Universität Dresden, Fetscherstrasse 74,  
01074 Dresden, germany 
Tel +49 351 4581 4544 
Fax +49 351 458 6344 
email susanne.fuessel@uniklinikum-
dresden.de
Purpose: To enhance prognostic information of protein biomarkers for clear cell renal cell 
carcinomas (ccRCCs), we analyzed them within prognostic groups of ccRCC harboring different 
tumor characteristics of this clinically and molecularly heterogeneous tumor entity.
Methods: Tissue microarrays from 145 patients with primary ccRCC were immunohistochemi-
cally analyzed for VHL (von Hippel-Lindau tumor suppressor), Ki67 (marker of proliferation 1), 
p53 (tumor protein p53), p21 (cyclin-dependent kinase inhibitor 1A), survivin (baculoviral IAP 
repeat containing 5), and UEA-1 (Ulex europaeus agglutinin I) to assess microvessel-density.
Results: When analyzing all patients, nuclear staining of Ki67 (hazard ratio [HR] 1.08, 95% 
confidence interval [CI] 1.04–1.12) and nuclear survivin (nS; HR 1.04, 95% CI 1.01–1.08) 
were significantly associated with disease-specific survival (DSS). In the cohort of patients with 
advanced localized or metastasized ccRCC, high staining of Ki67, p53 and nS predicted shorter 
DSS (Ki67: HR 1.07, 95% CI 1.02–1.11; p53: HR 1.05, 95% CI 1.01–1.09; nS: HR 1.08, 95% 
CI 1.02–1.14). In organ-confined ccRCC, patients with high p21-staining had a longer DSS 
(HR 0.96, 95% CI 0.92–0.99). In a multivariate model with stepwise backward elimination, 
tumor size and p21-staining showed a significant association with DSS in patients with “organ-
confined” ccRCCs. The p21-staining increased the concordance index of tumor size from 0.75 to 
0.78. In patients with “organ-confined” ccRCC, no disease-related deaths occurred in the group 
with p21-expression below the threshold of 32.5% p21-positive cells (log rank test: P=0.002).
Conclusion: The prognostic information of the studied protein biomarkers depended on 
anatomic tumor stages, which displayed different acquired biological tumor characteristics. 
Analysis of prognostic factors within different clinical ccRCC groups could help to enhance 
their prognostic power. The p21-staining was an independent prognostic factor and increased 
prognostic accuracy in a predictive model in “organ-confined” ccRCC.
Keywords: survival, prognostic groups, localized, p21, advanced
Introduction
Clear cell renal cell carcinomas (ccRCCs) have a very heterogeneous course of dis-
ease. To date, clinical outcome is not reliably predictable with established clinical and 
pathological factors. Many attempts were made to enhance the prognostic power of 
established markers, such as nomograms based on clinical and pathological variables 
and the evaluation of molecular markers.1 Nonetheless, TNM stage and Fuhrman grade 
still yield the highest prognostic power.2,3
Based on the TNM staging system, ccRCC can be classified into three major 
prognostic groups: “organ-confined” (pathological tumor stage, pT1-pT2; lymph 
node stage, N0; metastases stage, M0), “advanced localized” (pT3-pT4 N0 M0), and 
“metastasized” (any pT, N1, and/or M1) ccRCC2 with 5-year disease-specific survival 
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(DSS) rates from 82% to 95%,4 24% to 72%,5 and 5% to 
30%,6 respectively. These groups display different acquired 
characteristics of cancers such as tissue  invasion and metasta-
sis. Organ-confined ccRCC is nearly always present without 
invasion of the surrounding renal tissue.7 This is reflected in 
the low rate of distant metastasis between 4.2% and 7.1% in 
ccRCC #4 cm at initial presentation.8
Protein expression analysis of gene products with impor-
tant functions in tumorigenesis and with altered expression 
in cancer initiation and/or progression, respectively, can help 
to identify prognostic groups more accurately.3,9
Weiss et al showed that the predictive capability of the 
molecular biomarker p21 (cyclin-dependent kinase inhibi-
tor 1A) is dependent on ccRCC biology, with high nuclear 
p21-expression being associated with longer DSS in organ-
confined and advanced localized disease, but shorter survival 
in metastasized disease.10 High Ki67 (marker of prolifera-
tion 1)-expression, a measure of high proliferation activity, 
is a negative predictor of DSS in ccRCC patients.3 High 
p53-staining is associated with TP53-mutations and with 
shorter survival in ccRCC.1 p21 can arrest the cell cycle 
as an effector of p53, but also has p53-independent growth 
promotional,  pro-apoptotic, and anti-apoptotic effects in 
ccRCC.10 The inhibitor of apoptosis, survivin, is highly 
upregulated in ccRCC and associated with poor outcome.11,12 
VHL (von Hippel-Lindau tumor suppressor)-alterations are 
an initial step in the development of most ccRCC leading to 
angiogenesis, cell migration, and proliferation.1 In addition, 
VHL is a regulator of p53 stabilization.13 Angiogenesis was 
proven to be an important step in development and progres-
sion of ccRCC with microvessel density (MVD) as an easily 
assessable marker of tumor vascularization.14
These molecular markers reflect the complex interplay 
between apoptosis, cell cycle regulation, growth signaling, 
angiogenesis, and immortalization in ccRCC. In this study, 
we analyzed whether the immunohistochemical staining 
profiles of Ki67, p53, p21, nuclear survivin (nS), cytoplasmic 
survivin (cS), VHL, and MVD have distinct associations 
with clinical outcome in the subgroups of organ-confined or 
advanced localized and metastasized ccRCC. The primary 
aim of the present study is to identify if these molecular 
markers add prognostic information to established clinical 
and pathological markers in biologically distinct subgroups 
of ccRCC.
Materials and methods
Tissue specimens
Tumor specimens from 145 patients suffering from primary 
ccRCC with available paraffin blocks and follow-up data 
were analyzed retrospectively. All patients underwent total or 
partial nephrectomy at the Department of Urology Dresden 
between 1993 and 2000. Follow-up of patients was retrieved 
from in-house medical records and/or from the attending 
urologist or general practitioner. For all patients, histological 
classification and tumor grade according to Fuhrman were 
reevaluated on the histopathological slides in a blinded fash-
ion (by MM and TW). Tumor stage was reclassified according 
to the Union for International Cancer Control classification 
2009.15 Tissue collection and analysis was acknowledged 
by the internal review board of the Technical University of 
Dresden (EK59032007 and EK195092004). Patients gave 
written informed consent.
Tissue microarrays
Tissue microarrays (TMAs) were constructed including two 
representative tumor cores (one core from the center and one 
from the margin of the tumor) with a diameter of 0.6 mm 
from each patient. Selection of representative tissue areas was 
performed by a trained pathologist (MM) on large  sections 
for each ccRCC. Normal kidney specimens were used as 
controls. Specimens of 12 metastases were incorporated 
in the TMA. Sections of 4 µm thickness were mounted on 
adhesive glass slides. Quality control with regard to type of 
tissue and grade was performed on hematoxylin and eosin 
stained TMA sections.
immunohistochemistry
As previously described,16 all sections were deparaffinized and 
antigen retrieval for p21, survivin, and VHL was achieved by 
heating the sections in 0.01 M citrate buffer pH 6.0 at 120°C 
for 10 minutes. After blocking endogenous  peroxidase, and 
after incubation with the blocking serum  (universal ABC-AP 
Kit; Vector Laboratories, Inc.,  Burlingame, CA, USA), sec-
tions were incubated overnight at 4°C with the following 
primary antibodies: mouse monoclonal antihuman antibodies 
against p21 (clone 4D10; 1:80; Nova Castra, Newcastle upon 
Tyne, UK) and against VHL (clone immunoglobulin (Ig)32; 
1:50; BD  Biosciences, San Jose, CA, USA) as well as rab-
bit polyclonal antihuman survivin antibody (clone AF886; 
1:200; R & D Systems, Inc.,  Abingdon, UK). Detection was 
achieved by using an anti-mouse/anti-goat ABC-Kit and 
visualization was  accomplished with new fuchsine. For Ki67, 
p53, and UEA-1 (Ulex europaeus agglutinine-1), antigen 
retrieval was performed at 95°C for 20 minutes using 0.01 
M citrate buffer pH 6.0. Mouse monoclonal antihuman Ki67 
(clone MIB-1; 1:300; Dako, Glostrup, Denmark), p53 (clone 
DO-1; 1:100; Oncogene, Seattle, WA, USA), and UEA-1 
(clone B-1065; 1:10; Vector Laboratories, Inc.) antibodies 
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were used. After incubation with ABC-reagent (Vectastain 
Elite ABC Kit anti-mouse;  Vector Laboratories, Inc.), DAB 
(3,3’-Diaminobenzidin) was used for visualization and 
Meyer’s Hemalaun for  counterstaining. For every TMA-tissue 
core, the number of positively stained cells per 100 cells was 
evaluated manually by light microscopy at 400× magnifica-
tion blinded to the clinical data (performed by TW). The 
mean of two tumor-cores per case was calculated. Nuclear 
staining was evaluated for p21, p53, Ki67, and survivin. 
Cytoplasmic staining was evaluated for VHL and also for 
survivin. MVD was analyzed by the method of Weidner et al17 
using the expression of UEA-1 in endothelial cells. Random 
samples of all stainings were reevaluated by a second person 
(MM); no interobserver difference in marker expression of 
more than 10% was noted. No marked heterogeneity of any 
staining was observed in parallel analyzed large sections in 
a subset of patients.
statistical analysis
All protein markers were analyzed as continuous vari-
ables. Associations between protein markers and cat-
egorical  clinicopathological variables were analyzed by 
Mann– Whitney U test. DSS was measured as time from 
nephrectomy to death of disease. Uni- and multivariate sur-
vival analyses were performed with Cox proportional hazards 
regression models. Assumption of proportional hazards was 
tested for every variable by Schoenfeld’s partial residuals. 
Multivariate models were performed with stepwise Wald 
backward exclusion using 0.1, 0.15, and 0.2 as thresholds 
for exclusion. Hazard ratios (HRs) of the retaining variables 
were internally validated with bootstrapping analysis with 
1,000 samples, and predictive accuracies of the final models 
were quantified by using the concordance index. For easier 
assessment of marker expression in clinical routine, p21 
expression was classified into two categories: .32.5% (nor-
mal) and #32.5% (altered) cells with positive p21-staining as 
used by Weiss et al on renal cell carcinoma TMA sections.10 
Survival functions of categorized p21 staining were visualized 
with Kaplan–Meier plots, and differences between groups 
were assessed with log rank tests. Generally, P-values ,0.05 
were considered significant. Due to the explorative character 
of the study, we did not correct alpha-error due to multiple 
testing. Statistical analysis was accomplished with PASW 
18.0 (IBM Corporation, Armonk, NY, USA) and R 2.15.1 
(http://www.r-project.org).
Results
Twenty-eight of the 145 patients (19.3%) died of disease and 
27 (18.6%) died of other causes. Mean and median follow-up 
time of the surviving patients was 9.2 (standard error 4.1) and 
9.7 years (interquartile range [IQR] 8.8–10.5), respectively. 
Patient characteristics are given in Table 1.
Immunohistochemistry was evaluable in all cases for 
Ki67, in 144 cases for p21 and UEA-1, in 143 cases for 
p53 and VHL, and in 141 cases for survivin. Representative 
stainings are shown in Figure 1. The median percentage of 
positive-stained ccRCC cells for Ki67, p53, p21, cS, nS, and 
VHL were 5.5% (IQR 3–8.7), 15.5% (IQR 7–24.5), 26% 
(IQR 17–37.5), 34.5% (IQR 17–50.5), 6.5% (IQR 2.8–12.8), 
and 18% (IQR 4.5–28.5), respectively. Median vessel count 
according to Weidner et al17 was 19.5 (IQR 7.8–33.9). High 
Fuhrman grade (grade 3–4) was significantly associated 
Table 1 clinicopathological patient characteristics
Variable Categories Number  
of patients
n 145
sex Male 88 (60.7%)
Female 57 (39.3%)
age in years Median (iQr) 64 (57–71)
Tumor size in mm Median (iQr) 49 (33–70)
pT-stage pT1a 62 (42.8%)
pT1b 33 (22.8%)
pT2a 12 (8.3%)
pT2b 5 (3.4%)
pT3a 10 (6.9%)
pT3b 21 (14.5%)
pT3c 0
pT4 2 (1.4%)
n-stagea n0 137 (94.5%)
n1 8 (5.5%)
M-stage M0 140 (96.6%)
M1 5 (3.4%)
nM n and M negative 133 (91.7%)
n and/or M positive 12 (8.3%)
TnM-stage stage i 92 (63.4%)
stage ii 17 (11.7%)
stage iii 29 (20%)
stage iV 7 (4.8%)
Biological ccrcc groups Organ-confined  
(pT1-2 n0 M0)
109 (75.2%)
localized advanced  
(pT3-4 n0 M0)
24 (16.6%)
Metastasized (any  
pT, n1 and/or M1)
12 (8.3%)
Fuhrman grade g1 9 (6.2%)
g2 67 (46.2%)
g3 50 (34.5%)
g4 19 (13.1%)
Type of nephrectomy Total 143 (98.6%)
Partial 2 (1.4%)
systemic salvage treatment  
after relapse or progression
no 121 (90.4%)
Yes 14 (9.6%)
Note: aif no lymph nodes were resected, n-stage was clinically assessed.
Abbreviations: ccrcc, clear cell renal cell carcinomas; iQr, interquartile range; 
n, number; pT-stage, pathological tumor stage; n-stage, lymph node stage; M-stage, 
metastases stage; nM, lymph node and metastases stage; TnM-stage, tumor node 
metastases stage; g, grade.
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with higher median Ki67-staining, lymph node involvement 
with lower cS-staining, and MVD (Table S1). No other 
significant associations to clinicopathological parameters 
were observed.
In univariate Cox proportional hazards model analyses of 
the whole cohort, high pT stage, TNM stage, Fuhrman grade, 
larger tumor size, as well as positive N stage and M stage 
were predictors for a shorter DSS (Table 2).
For all analyzed protein marker variables, assumption 
of linearity could be made and Cox proportional hazard 
models were constructed. Higher Ki67- and nS-staining 
were associated with an 8% and 4% increased risk of death 
caused by ccRCC for every 1% increase in stained cells, 
respectively (Ki67: HR 1.08, 95% confidence interval [CI] 
1.04–1.12, P,0.001; nS: HR 1.04, 95% CI 1.01–1.08, 
P=0.016). Patients with higher p53-staining or lower MVD 
tended to have a higher risk of death due to ccRCC (p53: 
HR 1.03, 95% CI 0.96–1.06, P=0.096; MVD: HR 0.98, 95% 
CI 0.95–1, P=0.071). The other biomarkers were not predic-
tive for DSS (Table 2).
When analyzing the 36 patients with advanced local-
ized or metastasized ccRCC (pT3-4 N0 M0 or any pT, N1, 
A B
C D
E
50 µm
F
50 µm
50 µm 50 µm
50 µm
50 µm
Figure 1 representative ccrcc cores with positive immunohistochemical stainings.
Notes: (A) Ki67 with brown nuclear staining of the ccrcc-cells, sample number 95; (B) p53 with brown nuclear staining of the ccrcc cells, sample number 46; (C) p21 with 
red nuclear staining of the ccrcc-cells (arrows), sample number 192; (D) survivin with red nuclear (arrows) and cytoplasmic (arrowheads) staining of the ccrcc-cells, 
sample number 158; (E) Vhl with red cytoplasmic staining of the ccrcc-cells, sample number 182; (F) MVD with brown staining of endothelial cells, sample number 45; 
magnifications 400×.
Abbreviations: ccrcc, clear cell renal cell carcinomas; MVD, microvessel density; Vhl, von hippel-lindau tumor suppressor; Ki67, marker of proliferation 1; p53, tumor 
protein p53; p21, cyclin-dependent kinase inhibitor 1a; survivin, baculoviral iaP repeat containing 5.
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and/or M1, respectively) together, the presence of lymph 
node or distant metastasis were the strongest predictors for 
shorter DSS. Higher Fuhrman grade tended to be associ-
ated with DSS (Table 2). In these patients, Ki67-, p53-, and 
nS-stainings were significantly predictive for DSS (Ki67: 
HR 1.07, 95% CI 1.02–1.11, P=0.002; p53: HR 1.05, 95% 
CI 1.01–1.09, P=0.025; nS: HR 1.08, 95% CI 1.02–1.14, 
P=0.006; Table 2). These associations of Ki67-, p53-, and 
nS-stainings with DSS were also noticed in the 24 patients 
with advanced localized disease (Ki67: HR 1.08, 95% CI 
1–1.16, P=0.047; p53: HR 1.09, 95% CI 1.02–1.16, P=0.009; 
nS: HR 1.18, 95% CI 1.06–1.32, P=0.004; Table 2). We did 
not perform Cox proportional hazards model analysis for the 
subgroup of the 12 patients with metastasized ccRCC due 
to the small number.
For the 109 patients with organ-confined ccRCC (pT1-2 
N0 M0), larger tumor size as well as pT2 were associated with 
shorter DSS in univariate survival analyses (Table 2). Patients 
with higher p21-staining had a decreased risk of death due 
to ccRCC (HR 0.96, 95% CI 0.92–0.99, P=0.031). Hence, 
every 1% decrease of p21-staining increases risk of death 
due to ccRCC by 4%. No significant association to DSS was 
seen for the other biomarkers (Table 2).
After classification of the p21-staining in patients 
with normal (.32.5%) and altered (#32.5%) staining 
according to Weiss et al,10 68 patients with organ-confined 
ccRCC (63%) had an altered p21-staining. These patients 
had a significantly increased risk of death due to ccRCC 
(log rank test: P=0.002; Figure 2). This effect could be 
observed in patients with pT1a, pT1b, and pT2 tumors (log 
rank test for trend: P=0.009; Figure 2). Cox regression 
analysis could not be performed as no ccRCC-specific 
deaths occurred in the subgroup of patients with altered 
p21-staining.
These results indicate a differential prognostic impact of 
immunohistochemical staining signatures in  organ-confined, 
advanced localized, and metastasized ccRCC. Therefore, we 
performed multivariate analysis separately for organ-con-
fined ccRCC. The multivariate model comprised Fuhrman 
grade (grade 1 versus grade 2), tumor size, pT stage (pT1 
versus pT2), and continuous p21-staining. After stepwise 
backward deletion with different deletion thresholds, 
 continuous p21-staining and tumor size remained in the 
model. Consecutively, bootstrapping analysis was per-
formed for the remaining variables.  Continuous p21-stain-
ing and tumor size were independent prognostic factors for 
DSS in the group of organ-confined ccRCC (p21: HR 0.96, 
95% CI 0.92–0.99, P=0.027; tumor size: HR 1.02, 95% CI 
1.01–1.05, P=0.011). Compared to tumor size alone, inclu-
sion of continuous p21-staining increased the concordance 
index from 0.75 to 0.78.  However, this difference was not 
statistically significant. Due to the small numbers of patients 
Table 2 Univariate cox proportional hazards regression model analyses of clinicopathological and molecular variables for disease-
specific survival in all analyzed ccRCC patients as well as in the subgroups of patients with organ-confined disease, with advanced 
disease (advanced-localized and metastasized combined) and the subgroup of advanced-localized disease
Variable All cases, n=145 Organ-confined, n=109 Advanced, n=36 Advanced-localized, n=24
HR (95% CI); P HR (95% CI); P HR (95% CI); P HR (95% CI); P
pT-stage
 pT2 versus pT1 2.57 (0.9–7.33); 0.078 2.64 (0.92–7.56); 0.07 na na
 pT3-4 versus pT1 2.86 (1.26–6.49); 0.012 na na na
 Trend 0.029 na na na
n-stage (n1 versus n0) 10.43 (3.69–29.5); ,0.001 na 4.94 (1.49–16.4); 0.009 na
M-stage (M1 versus M0) 10.04 (3.34–30.1); ,0.001 na 4.51 (1.3–15.16); 0.015 na
TnM-stage (iii–iV versus i–ii) 3.52 (1.67–7.39); 0.001 na na na
Fuhrman grade  
(g3–4 versus g1–2)
2.92 (1.29–6.64); 0.01 2.17 (0.73–6.48); 0.166 3.5 (0.97–11.55); 0.055 4.6 (0.54–39.49); 0.163
Tumor size (mm) 1.02 (1.01–1.03); ,0.001 1.03 (1.01–1.04); 0.003 1.01 (1–1.02); 0.564 1.02 (0.99–1.04); 0.256
sex (male versus female) 1.36 (0.61–3); 0.451 1.67 (0.52–5.33); 0.387 1.99 (0.36–3.25); 0.88 1.17 (0.21–6.42); 0.856
Ki67 (%) 1.08 (1.04–1.12); ,0.001 1.04 (0.93–1.17); 0.458 1.07 (1.02–1.11); 0.002 1.08 (1–1.16); 0.047
p53 (%) 1.03 (0.96–1.06); 0.096 1.02 (0.97–1.07); 0.441 1.05 (1.01–1.09); 0.025 1.09 (1.02–1.16); 0.009
p21 (%) 0.98 (0.96–1.01); 0.149 0.96 (0.92–0.99); 0.031 1.01 (0.98–1.049); 0.711 1.02 (0.97–1.07); 0.424
cs (%) 1 (0.98–1.02); 0.952 1.01 (0.98–1.03); 0.55 1 (0.97–1.02); 0.924 1.02 (0.98–1.06); 0.407
ns (%) 1.04 (1.01–1.08); 0.016 1.03 (0.98–1.82); 0.31 1.08 (1.02–1.14); 0.006 1.18 (1.05–1.32); 0.004
Vhl (%) 1 (0.97–1.01); 0.409 1 (0.96–1.03); 0.803 0.99 (0.96–1.01); 0.368 0.98 (0.93–1.02); 0.322
MVD (%) 0.98 (0.95–1); 0.071 0.97 (0.93–1.01); 0.169 0.98 (0.95–1.01); 0.198 0.99 (0.96–1.03); 0.72
Note: Significant P-values are given in bold.
Abbreviations: ccRCC, clear cell renal cell carcinomas; CI, confidence interval; HR, hazard ratio; MVD, microvessel density; NA, not applicable; n, number; pT-stage, pathological 
tumor stage; n-stage, lymph node stage; M-stage, metastases stage; TnM-stage, tumor node metastases stage; g, grade; Vhl, von hippel-lindau tumor suppressor; Ki67, marker 
of proliferation 1; p53, tumor protein p53; p21, cyclin-dependent kinase inhibitor 1a; ns, nuclear survivin; cs, cytoplasmic survivin.
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with advanced localized or  metastasized disease, we did not 
construct multivariate models for these cohorts.
Discussion
In the last decades, substantial achievements in predicting 
disease-specific mortality of patients with ccRCC were made 
(eg, by further improvement of the TNM-staging system or 
by introduction of algorithms and nomograms incorporating 
clinical and pathological data).1,2 These scores, such as the 
SSIGN (Mayo Clinic “stage, size, grade, and necrosis” score) 
or Leibovich score have already been externally validated.18,19 
However, prediction of biology of ccRCC remains difficult 
0
100 + + + + + + +++++ ++++++ ++ +++++ ++ + + ++ ++ +
+ +++ ++
+++ ++++
+ +++++ ++
+++
++ +
++ +
+++++ ++ + +
2 4 6
Time from nephrectomy (years)
A
D
is
ea
se
-s
p
ec
if
ic
 s
u
rv
iv
al
 p
ro
b
ab
ili
ty
 (
%
)
8 10 12 14 16
90
p21≤32.5%
P=0.002
All organ-confined ccRCC
p21>32.5%
80
70
60
50
40
30
20
10
0
p21-expression
>32.5%
≤32.5%
Patients at risk (all)
40
68
37
62
34
57
29
48
26
39
18
24
11
12
7
3
1
–
Patients at risk (pT1a)
25
35
23
32
23
29
19
25
17
20
13
12
8
6
4
1
–
–
0
100 + +
+ ++
+ ++ +++ + +++++ + ++++ +
+++ + +
+ ++++ + + ++ +++ + ++ ++ + + + ++
2 4 6
Time from nephrectomy (years)
B
D
is
ea
se
-s
p
ec
if
ic
 s
u
rv
iv
al
 p
ro
b
ab
ili
ty
 (
%
)
8 10 12 14 16
90
p21≤32.5%
P=0.100
Organ-confined pT1a ccRCC
p21>32.5%
80
70
60
50
40
30
20
10
0
0
100 + + + + + + + + +
+ ++
+
+
+ +++
+
+ +++ + +
2 4 6
Time from nephrectomy (years)
C
D
is
ea
se
-s
p
ec
if
ic
 s
u
rv
iv
al
 p
ro
b
ab
ili
ty
 (
%
)
8 10 12 14 16
90
p21≤32.5%
P=0.102
Organ-confined pT1b ccRCC
p21>32.5%
80
70
60
50
40
30
20
10
0
p21-expression
>32.5%
≤32.5%
Patients at risk (pT1b)
9
22
9
20
8
18
8
15
8
12
7
7
4
5
3
2
1
–
Patients at risk (pT2a+b)
6
11
6
10
4
9
3
8
3
7
1
5
–
1
–
–
–
–
0
100
+
++
++
+
+ + + ++ +
2 4 6
Time from nephrectomy (years)
D
D
is
ea
se
-s
p
ec
if
ic
 s
u
rv
iv
al
 p
ro
b
ab
ili
ty
 (
%
)
8 10 12 14 16
90
p21≤32.5%
P=0.214
Organ-confined pT2a+b ccRCC
p21>32.5%
80
70
60
50
40
30
20
10
0
Figure 2 Kaplan–Meier plots for dichotomized p21-staining (.32.5% versus #32.5%). 
Notes: Disease-specific survival for patients after total or partial nephrectomy for organ-confined ccRCC (A) plot for all 108 patients with organ-confined ccRCC and 
evaluable p21-staining (pT1+2), (B) plot for the subgroup of 60 patients with pT1a, (C) for the 31 patients with pT1b, and (D) for the 17 patients with pT2a+b tumors. The 
tables under the plots display the number of patients at risk at the time points given on the x-axes. The log rank test for overall comparison of p21-expression groups adjusted 
for pT stage subgroups resulted in P=0.009. The P-values for the individual subgroups are shown in the plots.
Abbreviations: ccrcc, clear cell renal cell carcinomas; pT, pathological tumor stage; p21, cyclin-dependent kinase inhibitor 1a.
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and TNM-staging is currently the most relevant predictor of 
ccRCC.20 With increased understanding of tumor biology, 
molecular biomarkers are becoming an attractive target for 
improvement of prognosis prediction.6 Many studies analyz-
ing the prognostic value of biomarkers were conducted, but 
results were sometimes conflicting, potentially reflecting the 
nonuniform molecular changes in ccRCC during its evolu-
tion.21 For example, carbonic anhydrase IX is one of the most 
important predictors of survival in metastasized ccRCC but 
has no prognostic value in localized disease.22 Taking this 
into account, we stratified our analyses of the prognostic 
biomarkers in organ-confined ccRCC (noninvasive) as well 
as advanced localized and metastasized (invasive) ccRCC as 
organ-confined ccRCC do not usually invade the surrounding 
kidney tissue,7 which is a characteristic of more advanced 
tumors. In this study, immunohistochemical staining patterns 
of VHL, Ki67, p53, p21, nS, and cS as well as MVD were 
analyzed to investigate whether they displayed the hetero-
geneity of ccRCC.
The proliferation marker Ki67 is one of the best estab-
lished prognostic biomarkers for disease-specific recurrence 
in non-metastasized and metastasized ccRCC.3,23,24 In our 
patient cohort, high Ki67-staining was related to shorter 
DSS when analyzing all patients as well as the subgroup with 
advanced localized or metastasized ccRCC. In accordance 
with two studies analyzing Ki67-expression in pT1 renal 
cell carcinomas, we could not identify a relation to DSS in 
organ-confined ccRCC.25,26
The role of p53 in ccRCC is ambiguous.1 Whole genome 
sequencing of ccRCC revealed that p53 mutations are not 
frequent in ccRCC.21 However, high p53-expression is 
 associated with poor survival.3,24,27 In our cohort and the 
cohort of Kramer et al,28 p53-staining only tended to be 
associated with DSS, when evaluating all patients. In our 
study, it was not associated with survival in the subgroup 
of organ-confined ccRCC. However, in patients with 
advanced localized and metastasized ccRCC, p53-staining 
was significantly linked to DSS in our cohort, regardless 
of whether studied separately or combined. This indicates 
that indirect p53-alterations might be a later step in ccRCC 
progression.
The cell cycle control, microtubule stabilization, and 
antiapoptotic functions of survivin seem to be associated with 
intracellular protein localization.29 Similar to Parker et al,11 
we observed a significant relation between the expression of 
the nuclear survivin pool and prognosis when analyzing all 
patients. High nS-staining was associated with shorter DSS 
in patients with advanced localized and metastasized ccRCC 
or with locally advanced ccRCC only, but not in patients 
with organ-confined ccRCC. To our knowledge, no other 
study analyzed the value of nS-expression in organ-confined 
ccRCC. Parker et al,11 also observed a cS-staining in ccRCC 
but did not pursue it further. In our analysis, the cS-staining 
was not a predictor of prognosis for ccRCC, in contrast to 
another study on 85 ccRCC patients.12 One reason for the 
different results might be the antibodies used. We applied 
the commonly used polyclonal antibody AF886, whereas 
the monoclonal anti-survivin antibody used by Byun et al12 
might not detect all survivin splice variants.
Low MVD is strongly associated with advanced disease.14 
This might be a reason why MVD tended to be related with 
DSS in the whole cohort but lost its predictive ability when 
studied in the ccRCC subsets.
In a large cohort and in our study, VHL-staining was not 
associated with DSS.9 Possibly, VHL loss-of-function muta-
tions lead to decreased immunohistochemical staining, but 
patients with lack of VHL mutations and, thus, with high 
VHL-staining display a shorter DSS.30,31
Interestingly, in our study, high nuclear p21-staining 
was associated with longer DSS in organ-confined but not 
in advanced localized or metastasized ccRCC. This associa-
tion was seen when analyzing p21-staining as a continuous 
variable. Most notably, no disease-related death occurred in 
patients with altered p21-staining when p21-staining results 
were categorized according to Weiss et al.10 This group10 and 
Klatte et al22 also observed an association between high p21-
staining and favorable prognosis, but they included patients 
with organ-confined and advanced localized ccRCC. As both 
studies did not stratify the analysis of p21-staining for these 
two subgroups, it is unknown if this association would be 
more pronounced if the subgroup of organ-confined ccRCC 
was analyzed separately. In addition, p21-staining lost 
predictive ability when analyzed in patients with advanced 
localized ccRCC only.
In contrast to localized ccRCC, high nuclear p21-staining 
was associated with poor prognosis in metastasized disease 
in the study of Weiss et al.10 Analyzing the 12 patients with 
metastases, we observed a trend for a shorter DSS in patients 
with high nuclear p21-staining (data not shown). Stud-
ies evaluating p21-staining in localized and metastasized 
ccRCC together could not uncover its prognostic value.32,33 
Function of p21 depends on its subcellular localization. 
After  phosphorylation, p21 is localized in the cytoplasm 
and possesses p53-independent, growth promotional, and 
anti-apoptotic functions.10 In the study of Weiss et al, high 
cytoplasmic p21-staining was associated with shorter  survival 
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in metastasized ccRCC.10 Future studies on larger patient 
cohorts should elucidate the prognostic potential of subcel-
lular p21 localization.
In summary, these data suggest that p21 might play an 
ambiguous role in the biological behavior of ccRCC.  Consistent 
with that, p21 is involved in various opposing processes. 
Depending on conditions, it can act as inhibitor or promoter 
of cell cycle progression.34 Besides the antiapoptotic effects of 
the cytoplasmic phosphorylated form, it has many oncogenic 
transcriptional activities.34 In breast cancer, p21 is a downstream 
target of transforming growth factor (TGF)-β and is essential 
for tumor cell invasion.35 Interestingly, TGF-β is regulated via 
VHL in ccRCC.36,37 p21 possibly acts as cell cycle regulator in 
organ-confined ccRCC, but its function switches during ccRCC 
progression to promote cell migration and invasion.
In our multivariate analyses, p21-staining was an inde-
pendent predictor of DSS in organ-confined ccRCC and it 
enhanced the predictive ability of tumor size, whereas it was 
not an independent prognostic factor in the studies of Weiss 
et al10 and Klatte et al.22 Due to the low number of patients 
with advanced localized and metastasized disease, we only 
performed multivariate analyses for patients with organ-
confined ccRCC.
Kim et al3 first described that incorporation of the inde-
pendent survival predictors p53, vimentin, and carbonic 
anhydrase IX in a system of clinical markers improved 
predictive ability in nonselected ccRCC from 0.75 to 0.79. 
To our knowledge, the present analysis is the first study 
evaluating prognostic ability of biomarkers in the subset of 
organ-confined ccRCC. However, due to the high predictive 
accuracy (up to 88%) of prognostic models based only on 
clinical and radiological parameters, to date, none of the 
prognostic models incorporating biomarkers are recom-
mended for routine use.1,20
Our analysis is mainly limited by the retrospective design, 
a relatively limited number of cases, and the small number 
of patients with metastases. The multiple testing procedures 
could have led to significant associations by chance, even if 
we evaluated results not only by statistical but also clinically 
immanent association. Due to the explorative design of the 
study, we did not use procedures to reduce alpha-error besides 
bootstrapping analysis in the multivariate model. Therefore, 
independent external validation of these data is needed to sup-
port our findings. After testing for nonlinearity, we analyzed 
all biomarkers as continuous variables to avoid insignificant 
associations by arbitrarily chosen cutoff values.
The study is further limited by the lack of stan-
dards for staining technique, storage, and f ixation of 
 immunohistochemical procedures. We used normal renal 
tissue as negative control in our study. Recent studies using 
techniques such as exome gene sequencing revealed an 
underestimated heterogeneity by analyzing only a few parts of 
the tumor.38 To address this, we analyzed two TMA cores per 
tumor. Immunohistochemical studies revealed that, even in 
tumors with higher intratumor heterogeneity than ccRCC, the 
evaluation of two TMA cores leads to accordance of staining 
results with whole section slides in 90%–95% of cases.39 For 
all analyzed proteins, the percentage of positive-stained cells 
between tumor center and periphery correlated significantly 
(P,0.001, data not shown).
The evaluation of prognostic factors stratified to ccRCC 
subgroups helped to enhance their prognostic ability in the 
context of the varying tumor biology and the molecular 
evolution of this disease. Embedded in the literature, these 
data will help to improve the prediction of disease-specific 
 mortality and disclose targets for targeted therapy. For a 
robust conclusion regarding the prognostic value of p21-
staining in organ-confined ccRCC shown in the present study, 
it should be validated in larger independent cohorts.
Conclusion
The analyzed molecular markers had distinct  associations 
with prognosis when stratified to clinical and tumor biological 
subgroups. High expression of Ki67, nS, and p53 were sig-
nificantly associated with worse disease-specific mortality 
in localized advanced or metastasized ccRCC. In contrast, 
p21-staining was only associated with prognosis in organ-
confined disease. p21-expression remained a significant 
survival predictor in multivariate analyses. Further analyses 
are needed to confirm this association.
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Supplementary material
Table S1 Median staining frequencies of the analyzed immunohistochemical markers and MVD in primary ccrcc dependent on 
clinicopathological variables of the patients
Variable Patients Median staining frequencies Median 
MVDKi67 p53 p21 cS nS VHL
pT stage P=0.536 P=0.225 P=0.495 P=0.170 P=0.581 P=0.855 P=0.338
 1–2 112 6 16 26 34.8 7 18 21
 3–4 33 5 11 25 29.5 6 17 11.5
n-stage P=0.109 P=0.854 P=0.541 P=0.021 P=0.696 P=0.279 P=0.033
 n0 137 5.5 15 26 34.5 6.5 18.5 21
 n1 8 7 18 24 8 6 5 10.5
M-stage P=0.063 P=0.733 P=0.488 P=0.851 P=0.244 P=0.288 P=0.930
 M0 140 5.5 15 26 34 6.5 18 19.5
 M1 5 8.5 20 23 33 6.5 5 11.5
TnM-stage P=0.858 P=0.161 P=0.343 P=0.108 P=0.613 P=0.852 P=0.352
 i–ii 109 6 16 26 35 7 18 21
 iii–iV 36 5 10.5 24 29 6.5 17.8 12
Fuhrman grade P=0.007 P=0.392 P=0.201 P=0.295 P=0.104 P=0.140 P=0.306
 g1–2 76 5 16.5 28 32 7 14.5 21.5
 g3–4 69 7 13 23.5 37.5 6 21.5 17
Note: Significant P-values given in bold.
Abbreviations: ccrcc, clear cell renal cell carcinomas; cs, cytoplasmic survivin; MVD, microvessel density; ns, nuclear survivin; pT-stage, pathological tumor stage; n-stage, 
node stage; M-stage, metastases stage; TnM-stage, tumor node metastases stage; g, grade; Vhl, von hippel-lindau tumor suppressor; Ki67, marker of proliferation 1; p53, 
tumor protein p53; p21, cyclin-dependent kinase inhibitor 1a.
